Anti-PD-1/PD-L1 immunotherapy has demonstrated significant therapeutic efficacy in patients with locally advanced, unresectable, or metastatic tumors that express PD-1 or PD-L1 (programmed cell death receptor 1 and programmed cell death ligand 1, respectively) (42). Here, CD274 is linked to metastatic neoplasm.